- Home
- IMCR vs WB Comparison
IMCR vs WB Comparison
Compare IMCR & WB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMCR | WB |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United Kingdom | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2016 | 2014 |
Fundamental Metrics
Financial Performance| Metric | IMCR | WB |
|---|---|---|
| Price | $37.40 | $7.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | ★ $66.33 | $14.00 |
| AVG Volume (30 Days) | 406.6K | ★ 1.0M |
| Earning Date | 05-07-2026 | 05-28-2026 |
| Dividend Yield | N/A | ★ 7.49% |
| EPS Growth | ★ 30.39 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $249,428,000.00 | N/A |
| Revenue This Year | $14.57 | $8.35 |
| Revenue Next Year | $8.21 | $1.73 |
| P/E Ratio | $159.17 | ★ $5.66 |
| Revenue Growth | ★ 43.05 | N/A |
| 52 Week Low | $27.56 | $6.89 |
| 52 Week High | $40.71 | $12.96 |
Technical Indicators
Market Signals| Indicator | IMCR | WB |
|---|---|---|
| Relative Strength Index (RSI) | 65.81 | 29.64 |
| Support Level | $35.46 | $7.09 |
| Resistance Level | $37.25 | $7.78 |
| Average True Range (ATR) | 1.27 | 0.16 |
| MACD | 0.19 | -0.10 |
| Stochastic Oscillator | 90.54 | 18.30 |
Price Performance
Historical ComparisonAbout IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About WB Weibo Corporation
Weibo Corp is a China-based company that operates a social media platform for people to create, discover and distribute content. The company currently operates and manages its business in two principal business lines globally - advertising and marketing services and value-added services. The Value-added Services mainly provide services such as membership services on social platforms, online games, live broadcasts, social e-commerce, and others. The company's main product is the social platform Weibo. It generates a substantial majority of its revenues from online advertising and marketing services.